Replimune RP1 BLA Resubmission Accepted by FDA; PDUFA Date Set for Apr

In-Depth Analysis

Replimune's RP1 (vusolimogene oderparepvec) is an oncolytic immunotherapy based on a herpes simplex virus strain. It is engineered with a fusogenic protein and GM-CSF to maximize tumor cell death, enhance immunogenicity, and activate a systemic anti-tumor immune response.

The resubmission addresses feedback from a complete response letter (CRL) issued by the FDA in July 2025&ref=yanuki.com. The FDA now considers the resubmission a complete response to the CRL, which allows the review process to move forward.

The therapy targets advanced melanoma patients who have progressed on anti-PD-1 therapies, representing a population with significant unmet medical needs.

Replimune is also exploring the potential of RP1 in combination with other treatment modalities, highlighting the versatility of the RPx platform.

Read source article

FAQ

What is the PDUFA date for RP1?

The FDA set a PDUFA target action date of April 10, 2026&ref=yanuki.com.

What was the FDA's previous response to the RP1 application?

The FDA issued a complete response letter in July 2025&ref=yanuki.com, which Replimune has addressed in this resubmission.

What patient population would benefit from RP1?

RP1 is intended for patients with advanced melanoma who have progressed on an anti-PD-1 containing regimen.

Takeaways

Replimune's RP1 has the potential to become a valuable treatment option for advanced melanoma patients who have progressed on anti-PD-1 therapy.
The FDA's acceptance of the BLA resubmission signifies a critical milestone in the drug's regulatory pathway.
Investors and patients should monitor the FDA's review process, with a decision expected by the PDUFA date of April 10, 2026&ref=yanuki.com.

Discussion

Do you think this trend will last? Let us know!

Share this article with others who need to stay ahead of this trend!

Sources

PDUFA Apr 10, 2026: Replimune's BLA Resubmission for RP1 Accepted by FDA for Advanced Melanoma FDA accepts Replimune’s resubmitted BLA for melanoma treatment By Investing.com Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.

Replimune RP1 BLA Resubmission Accepted by FDA; PDUFA Date Set for April 10, 2026

Key Insights

In-Depth Analysis

FAQ

What is the PDUFA date for RP1?

What was the FDA's previous response to the RP1 application?

What patient population would benefit from RP1?

Takeaways

Discussion

Sources

Disclaimer

Replimune RP1 BLA Resubmission Accepted by FDA; PDUFA Date Set for April 10, 2026

Key Insights

In-Depth Analysis

FAQ

What is the PDUFA date for RP1?

What was the FDA's previous response to the RP1 application?

What patient population would benefit from RP1?

Takeaways

Discussion

Sources

Disclaimer

Related Stories